Quarterly

From the email in december. Considering we are a third of the way through the quarter we should expect some positive news very soon. OR we are stuffed.
1. Recruitment and dosing are on track for Q1 next year.
2. As part of our business development program we are continuing to explore large commercial opportunities within the North American consumer market. I travelled to the US earlier in the year to initiate discussions with several companies related to our TPM cannabinoid products. Feedback has been positive and testing of TPM-enhanced cannabinoid products is currently underway at a number of North American facilities, with the aim of entering subsequent licensing and supply agreements.
3. Our non-CBD licensing deals exploiting the unique properties of TPM continue to advance. Our topical Ibuprofen gel under investigation by Perrigo continued through the manufacturing phase of product development in anticipation of clinical studies in a pain indications
4. Additionally, the Arthur Group commenced formulation development of TPM enhanced oncology, using TPM to replace adverse excipients included in existing products that have known safety concerns.
5. Further business development activities will kick off early in 2024 as members of our team fly to San Francisco to attend the Biotech Showcase and meet companies attending the J.P. Morgan 42nd Annual Healthcare Conference.